Voriconazole and squamous cell carcinoma after lung transplantation: A multicenter study

B. Hamandi1 | C. Fegbeutel2 | F. P. Silveira3 | E. A. Verschuuren4 | M. Younus5 | J. Mo5 | J. Yan5 | P. Ussetti6 | P. V. Chin-Hong7 | A. Sole8 | C. L. Holmes-Liew9 | E. M. Billaud10 | P. A. Grossi11 | O. Manuel12 | D. J. Levine13 | R. G. Barbers14 | D. Hadjiliadis15 | J. Aram5 | L. G. Singer16 | S. Husain17

1Department of Pharmacy, University Health Network, Toronto, ON, Canada
2Department of Cardiothoracic, Transplant, and Vascular Surgery, Hannover Medical School, Hannover, Germany
3Division of Infectious Diseases, University of Pittsburgh Medical Center, Pittsburgh, PA, USA
4Department of Pulmonary Diseases, University Hospital Groningen, Groningen, the Netherlands
5Pfizer Inc., New York, NY, USA
6Respiratory Department, Hospital Puerta de Hierro, Madrid, Spain
7Department of Medicine, University of California, San Francisco, San Francisco, CA, USA
8Respiratory Department, University and Polytechnic Hospital La Fe, Universidad de Valencia, Valencia, Spain
9Lung Research, Hanson Institute, and Department of Thoracic Medicine, Royal Adelaide Hospital, Adelaide, Australia
10Service de Pharmacologie, AP-HP, Hôpital Européen G Pompidou, Paris, France
11Infectious Diseases Department, University of Insubria, Varese, Italy
12Infectious Diseases Service and Transplantation Center, University Hospital of Lausanne, Lausanne, Switzerland
13Division of Pulmonary and Critical Care Medicine, University of Texas Health Science Center San Antonio, San Antonio, TX, USA
14Division of Pulmonary and Critical Care, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA
15Department of Medicine, University of Pennsylvania, Hospital of the University of Pennsylvania, Philadelphia, PA, USA
16Toronto Lung Transplant Program, University Health Network, Toronto, ON, Canada
17Multi-Organ Transplant Program, University Health Network, Toronto, ON, Canada

Correspondence
Shahid Husain
Email: Shahid.Husain@uhn.ca

This study evaluated the independent contribution of voriconazole to the development of squamous cell carcinoma (SCC) in lung transplant recipients, by attempting to account for important confounding factors, particularly immunosuppression. This international, multicenter, retrospective, cohort study included adult patients who underwent lung transplantation during 2005-2008. Cox regression analysis was used to assess the effects of voriconazole and other azoles, analyzed as time-dependent variables, on the risk of developing biopsy-confirmed SCC. Nine hundred lung transplant recipients were included. Median follow-up time from transplantation to end of follow-up was 3.51 years. In a Cox regression model, exposure to voriconazole alone (adjusted hazard ratio 2.39, 95% confidence interval 1.31-4.37) and exposure to voriconazole and other azole(s) (adjusted hazard ratio 3.45, 95% confidence interval 1.07-11.06) were associated with SCC compared with those unexposed after controlling for important

Abbreviations: CI, confidence interval; CMV, cytomegalovirus; CNI, calcineurin inhibitor; COPD, chronic obstructive pulmonary disease; D, donor; DDD, defined daily dose; HR, hazard ratio; IA, invasive aspergillosis; ICU, intensive care unit; ILD, interstitial lung disease; IPF, interstitial pulmonary fibrosis; LT, lung transplant, transplantation; R, recipient; Ref, reference category; SCC, squamous cell carcinoma.
1 | INTRODUCTION

Skin cancer is the most common malignancy reported in recipients of solid organ transplants, with squamous cell carcinoma (SCC) of the skin being most frequently diagnosed. The incidence of SCC in recipients of solid organ transplants is 60 times that of the general population, but varies by organ transplant. Risk factors for the development of SCC include prolonged exposure to sunlight, long duration of immunosuppressive therapy, infection with human papillomavirus, lower CD4 cell counts, and certain host factors, such as male sex, older age, white race, and Fitzpatrick skin types I to III. The rates of all skin cancers among adult lung transplant (LT) recipients surviving 1, 5, and 10 years after transplantation have been reported to be 1.3%, 11.9%, and 20.8%, respectively. LT recipients may be particularly vulnerable for developing SCC as a result of concurrent intensity of immunosuppression.

Fungal infection is also an important complication for LT recipients, with 15% to 35% of patients being diagnosed with fungal infections, such as invasive aspergillosis (IA). The treatment of IA in LT recipients generally involves minimizing immunosuppression, followed by early initiation of a suitable antifungal agent until resolution of the pulmonary lesions.

Voriconazole (VFEND; Roerig, Pfizer, New York, NY) was approved in 2002 for the treatment of IA and other invasive fungal infections. Voriconazole was also recently approved for prophylaxis of invasive fungal infections in high-risk recipients of hematopoietic stem cell transplantations in the European Union and other countries. In addition to its approved indications, many transplant programs have implemented universal antifungal prophylaxis using voriconazole to prevent IA in recipients of LTs or heart-lung transplants. Data from a worldwide survey showed that voriconazole is the most widely prescribed antifungal agent for prophylaxis in LT recipients.

Single cases and small case series of SCC in voriconazole-treated immunocompromised patients have been reported, including in recipients of solid organ transplants and those with hematologic malignancies or human immunodeficiency virus infection. The risk of SCC or nonmelanoma skin cancer with voriconazole exposure has been investigated in single-center, retrospective, observational case-control or cohort studies, primarily among recipients of LTs, but also in recipients of hematopoietic stem cell transplants. Although most studies reported that exposure to voriconazole increased the risk of skin cancer, findings were not generally consistent, perhaps due to the differences in the exposure/endpoint assessments and/or analytical methods used. Also, some of the studies did not control for the presence of comorbidities or underlying conditions, sun exposure, or the use of potentially phototoxic concomitant medications, nor did they adequately account for immunosuppressives or antifungal agents, other than voriconazole, received by transplant recipients.

Given the limitations of the currently available data, the objective of this study was to assess the independent contribution of voriconazole to the development of SCC in LT or heart-lung transplant recipients, by accounting for important confounding factors, particularly comorbidities and the use of concomitant immunosuppressants and other azoles.

2 | METHODS

2.1 | Study design and patients

This multicenter, retrospective cohort study used patient-level data collected from 14 LT centers across 9 countries: United States, Canada, France, Germany, Italy, the Netherlands, Spain, Switzerland, and Australia. Consecutive patients aged ≥18 years who underwent single LT, double LT, or heart-lung transplantation at the participating study centers between January 1, 2005, and December 31, 2008, were eligible for inclusion (Figure 1). Patients with simultaneous or sequential abdominal organ transplant and those with a previous history of biopsy-confirmed SCC were excluded. The study protocol was approved by the University Health Network Research Ethics Board (REB No. 10-0622-AE) as the coordinating site and by institutional review boards and/or independent ethics committees at each site.

2.2 | Exposure

Cumulative voriconazole exposure of ≥30 days, not necessarily consecutive, was considered clinically meaningful for the risk of SCC; the same criterion was applied to other azoles. Sensitivity analysis using a cumulative exposure of 1 day was also conducted. LT recipients with...
any indication for voriconazole (or otherazole) use, including prophylaxis, empiric treatment, or targeted treatment, were included. The “index date” was the date of LT. Exposures to voriconazole and other azoles were analyzed as time-dependent variables and measured as person-time of exposure (Appendix S1 illustrates determination of treatment exposure categories at each time point during follow-up, with the use of hypothetical examples). At each post-LT time point, time-dependent exposure was classified into 1 of 4 treatment categories:

1. Unexposed to anyazole or exposed to someazole for <30 days (referred to as “unexposed”)
2. Exposed to voriconazole for ≥30 days but not to any otherazole for ≥30 days (referred to as “exposed to voriconazole alone”)  
3. Exposed to otherazole(s) for ≥30 days but not to voriconazole for ≥30 days (referred to as “exposed to other azoles alone”)  
4. Exposed to voriconazole for ≥30 days as well as exposed to some otherazole for ≥30 days (referred to as “exposed to voriconazole and other azoles”).

Finally, to assess the possibility that the risk of SCC may be dose dependent, we modelled exposure to voriconazole based on the mean cumulative daily dose, measured as “defined daily doses.”

2.3 Covariates

Comprehensive data were collected on demographic and clinical characteristics including potential confounders and effect modifiers for SCC. In addition to the use of immunosuppressive agents post-LT and potentially phototoxic agents, data on whole blood concentrations of calcineurin inhibitors and number of episodes of elevated calcineurin inhibitor levels were collected (Appendix S2 presents all covariates and their transformation).

2.4 Outcome assessment

The primary outcome was the first occurrence of biopsy-confirmed SCC during the follow-up period from the index date of LT. Recipients of LTs were followed from the index date to whichever of the following occurred first: SCC, death, last patient visit (based on documentation in the medical records), or December 31, 2012.

2.5 Statistical analysis

Assuming an incidence of SCC in LT recipients unexposed to voriconazole of 5% and a voriconazole exposed:unexposed ratio of 1:2, at least 157 LT recipients in the voriconazole-exposed cohort and 314 LT
recipients in the unexposed cohort were needed to detect a relative risk of 2.5 with 80% power at a 5% significance level. As a single patient may have contributed to >1 exposure category, for the baseline descriptive analysis, LT recipients were categorized into 2 categories: ≥1 day of exposure to voriconazole and no exposure to voriconazole. Unadjusted incidence rates of SCC were estimated during the total person-time of observation for the 4 treatment exposure categories, as described earlier.

Multivariate Cox proportional hazards models using fixed and time-dependent exposure categories for voriconazole were developed to control for the effect of known and potential confounding covariates decided a priori (age, sex, immunosuppression regimen, mean cyclosporine level, mean tacrolimus level, sun exposure, history of malignancy pretransplantation, transplant rejection episodes, underlying disease). Separate adjusted multivariate Cox proportional hazards models were also developed to assess the potential time-dependent effect of dose (measured in defined daily doses) and duration of voriconazole on the risk of SCC. The assumption of proportionality was graphically examined using log (cumulative hazard) plots and scaled Schoenfeld residuals.

All data were analyzed by using StataMP 12.1 (StataCorp LP, College Station, TX).

3 RESULTS

Nine hundred twenty-one consecutive patients aged ≥18 years were eligible for evaluation. Eight patients with simultaneous or sequential abdominal organ transplant were excluded, plus 13 patients with a pretransplantation history of SCC. Median follow-up time for the remaining patients (n = 900) from LT to the end of follow-up was 3.51 years (range, 1 day to 7.97 years). Of 900 LT recipients, 440 (48.9%) were from Europe, 430 (47.8%) were from North America, and 30 (3.3%) were from Australia. Overall, LT recipients had a median age of 53 years, 53.1% were male, and the primary indications for LT were chronic obstructive pulmonary disease (28.7%), interstitial pulmonary fibrosis (24.4%), and cystic fibrosis (22.3%).

Most LT recipients received a concomitant immunosuppressive regimen that included tacrolimus (70.7%) or a mycophenolate derivative (77.3%), and almost all (98.7%) had been exposed to corticosteroids. Forty-five percent (401 of 900) of LT recipients were exposed to voriconazole for ≥30 days, and approximately one-third were exposed to an azole other than voriconazole, including itraconazole (21.4%), fluconazole (5.8%), and posaconazole (4.6%). Table 1 summarizes LT recipients’ demographic and clinical characteristics. Of 472 LT recipients with ≥1-day exposure to voriconazole, 301 (63.8%) received voriconazole for prophylaxis, 132 (28.0%) received voriconazole for directed or empiric treatment, and 39 (8.3%) received voriconazole for both prophylaxis and treatment. Overall, slightly higher proportions of LT recipients with ≥1-day exposure to voriconazole than no exposure to voriconazole were classified in geographical areas with medium and high exposure to sunlight (medium sun exposure 59.3% vs 54.9%, high exposure to sunlight (medium sun exposure 59.3% vs 54.9%, high

| Characteristic | Voriconazole exposed (≥1-day exposure to voriconazole) (n = 472) | Voriconazole unexposed (no exposure to voriconazole) (n = 428) | All study patients (n = 900) |
|---------------|---------------------------------------------------------------|---------------------------------------------------------------|-----------------------------|
| Demographic characteristics | | | |
| Age, y | | | |
| 18-29 | 48 11.2 | 97 20.6 | 145 16.1 |
| 30-49 | 119 27.8 | 132 28 | 251 27.9 |
| 50-59 | 163 38.1 | 110 23.3 | 273 30.3 |
| >70 | 97 22.7 | 116 24.6 | 213 23.7 |
| Sex | | | |
| Male | 218 50.9 | 260 55.1 | 478 53.1 |
| Female | 210 49.1 | 212 44.9 | 422 46.9 |
| Occupationa | | | |
| Indoor | 130 30.4 | 255 54 | 385 42.8 |
| Outdoor | 21 4.9 | 36 7.6 | 57 6.3 |
| Mixed | 277 64.7 | 181 38.3 | 458 50.9 |
| Geographical location | | | |
| Australia | 15 3.5 | 15 3.2 | 30 3.3 |
| Canada | 149 34.8 | 79 16.7 | 228 25.3 |
| France | 4 0.9 | 23 4.9 | 27 3.0 |
| Germany | 94 22 | 101 21.4 | 195 21.7 |
| Italy | 26 6.1 | 0 0 | 26 2.9 |
| Netherlands | 64 15 | 27 5.7 | 91 10.1 |
| Spain | 59 13.8 | 25 5.3 | 84 9.3 |
| Switzerland | 10 2.3 | 7 1.5 | 17 1.9 |
| United States | 7 1.6 | 195 41.3 | 202 22.4 |
| Sun exposureb | | | |
| Low | 172 40.2 | 159 33.7 | 331 36.8 |
| Medium | 235 54.9 | 280 59.3 | 515 57.2 |
| High | 21 4.9 | 33 7.0 | 54 6.0 |
| Clinical characteristics | | | |
| LT type | | | |
| Double | 332 77.6 | 379 80.3 | 711 79 |
| Heart-lung | 14 3.3 | 13 2.8 | 27 3.0 |
| Single | 82 19.2 | 80 17.0 | 162 18.0 |
| Re-LT | | | |
| No | 409 95.6 | 449 95.1 | 858 95.3 |
| Yes | 19 4.4 | 23 4.9 | 42 4.7 |
| Underlying disease | | | |
| COPD | 140 32.7 | 118 25 | 258 28.7 |
| Characteristic                        | Voriconazole unexposed (no exposure to voriconazole) (n = 428) | Voriconazole exposed (≥1-day exposure to voriconazole) (n = 472) | All study patients (n = 900) |
|--------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|-----------------------------|
|                                      | n | %            | n | %            | n | %            |
| IPF                                  | 99 | 23.1         | 121 | 25.6         | 220 | 24.4         |
| Cystic fibrosis                      | 69 | 16.1         | 132 | 28           | 201 | 22.3         |
| α₁-Antitrypsin                       | 29 | 6.8          | 18  | 3.8          | 47  | 5.2          |
| Primary pulmonary hypertension       | 14 | 3.3          | 14  | 3.0          | 28  | 3.1          |
| Bronchiolitis obliterans             | 11 | 2.6          | 8   | 1.7          | 19  | 2.1          |
| Scleroderma                          | 9  | 2.1          | 10  | 2.1          | 19  | 2.1          |
| Sarcoidosis                          | 7  | 1.6          | 9   | 1.9          | 16  | 1.8          |
| ILD                                  | 6  | 1.4          | 3   | 0.6          | 9   | 1.0          |
| Other                                | 44 | 10.3         | 39  | 8.3          | 83  | 9.2          |
| Immune disorder                      | No | 420 | 98.1 | 465 | 98.5 | 885 | 98.3 |
|                                      | Yes | 8  | 1.9  | 7  | 1.5  | 15  | 1.7 |
| Other cancer pre-LT                  | Yes | 2  | 0.5  | 0  | 0.0  | 2   | 0.2 |
|                                      | No | 426 | 99.5 | 472 | 100 | 898 | 99.8 |
| Dialysis 30 days post-LT             | No | 414 | 96.7 | 459 | 97.2 | 873 | 97 |
|                                      | Yes | 14 | 3.3  | 13 | 2.8  | 27  | 3.0 |
| Transplant rejection episodes        | 0  | 240 | 56.1 | 213 | 45.1 | 453 | 50.3 |
|                                      | 1-2 | 136 | 31.8 | 184 | 39    | 320 | 35.6 |
|                                      | 3-4 | 41  | 9.6  | 46  | 9.7   | 87  | 9.7 |
|                                      | >4  | 11  | 2.6  | 29  | 6.1   | 40  | 4.4 |
| Neutropenia episodes                 | 0  | 183 | 42.8 | 157 | 33.3  | 340 | 37.8 |
|                                      | 1-2 | 140 | 32.7 | 152 | 32.2  | 292 | 32.4 |
|                                      | 3-4 | 63  | 14.7 | 63  | 13.3  | 126 | 14.1 |
|                                      | >4  | 42  | 9.8  | 100 | 21.2  | 142 | 15.8 |
| Diabetes post-LT                     | No | 332 | 77.6 | 328 | 69.5  | 660 | 73.3 |
|                                      | Yes | 83  | 19.4 | 122 | 25.8  | 205 | 22.8 |
|                                      | Missing | 13 | 3.0  | 22 | 4.7   | 35  | 3.9 |
| CMV                                  | D'R | 84  | 19.6 | 105 | 22.2  | 189 | 21.0 |
|                                      | D'R' | 112 | 26.2 | 142 | 30.1  | 254 | 28.2 |
|                                      | D'R | 102 | 23.8 | 86  | 18.2  | 188 | 20.9 |
|                                      | D'R' | 67  | 15.7 | 101 | 21.4  | 168 | 18.7 |
|                                      | Missing | 63 | 14.7 | 38  | 8.1   | 101 | 11.2 |

(Continues)
TABLE 1 (Continued)

| Characteristic | Voriconazole unexposed (no exposure to voriconazole) (n = 428) | Voriconazole exposed (≤1-day exposure to voriconazole) (n = 472) | All study patients (n = 900) |
|----------------|---------------------------------------------------------------|---------------------------------------------------------------|-----------------------------|
| Azathioprine use |                                               |                                               |                             |
| No             | 228                                            | 335                                            | 563                         | 62.6 |
| Yes            | 200                                            | 137                                            | 337                         | 37.4 |
| Sirolimus use  |                                               |                                               |                             |
| No             | 413                                            | 421                                            | 834                         | 92.7 |
| Yes            | 15                                             | 10.8                                           | 66                          | 7.3  |
| Everolimus use |                                               |                                               |                             |
| No             | 391                                            | 442                                            | 833                         | 92.6 |
| Yes            | 37                                             | 6.4                                            | 67                          | 7.4  |
| Potentially phototoxic drug use | | | |
| Phototoxic drug useb | | | |
| No             | 327                                            | 345                                            | 672                         | 74.7 |
| Yes            | 101                                            | 127                                            | 228                         | 25.3 |

CMV, cytomegalovirus; CNI, calcineurin inhibitor; COPD, chronic obstructive pulmonary disease; D, donor; ICU, intensive care unit; ILD, interstitial lung disease; IPF, interstitial pulmonary fibrosis; LT, lung or heart-lung transplantation; R, recipient.

aSubjectively classified according to whether subject would spend majority of time indoors/outdoors/mixed.

bAccording to respective study center’s geographical location by latitude: low (>45° latitude), medium (35-45° latitude), high (<35° latitude).

Includes rheumatoid arthritis, systemic lupus erythematosus, Henoch-Schönlein purpura, and psoriasis.

Not including squamous cell carcinoma, basal cell carcinoma, and melanoma.

Absolute neutrophil counts <500 cells/mm³.

Elevated CNI levels were defined as cyclosporine trough >350 μg/L or tacrolimus trough >20 μg/L.

 Patients receiving at least 1 dose were classified as being exposed.

Includes doxycycline, hydroxychloroquine, nifedipine, diltiazem, glyburide, naproxen, piroxicam, and isotretinoin.

Patients receiving at least 1 dose were classified as being exposed.

Includes doxycycline, hydroxychloroquine, nifedipine, diltiazem, glyburide, naproxen, piroxicam, and isotretinoin.

Sun exposure 7.0% vs 4.9%). Phototoxic reactions were recorded in 15 LT recipients overall, all of whom were exposed to voriconazole.

3.1 Incidence of SCC

Of the 900 LT recipients, 55 developed SCC. Median age was 58 years (range, 18-75 years), most were male (62%), and the majority had undergone double LT (78%) and had been diagnosed with interstitial pulmonary fibrosis (40%) or chronic obstructive pulmonary disease (29%). Median time from LT to development of SCC was 3.3 years (interquartile range 1.8-4.2 years). The crude incidence rate (per 1000 person-years) of SCC was 33.4 in the exposure to voriconazole alone category, 21.7 in the exposure to voriconazole and other azole(s) category, 10.4 in the exposure to other azoles alone category, and 13.1 in the unexposed category. Overall, a gradual increase in incidence rate of SCC was observed with increase in time since LT in the unexposed, voriconazole alone, and other azole alone exposure categories (Table 2).

3.2 Voriconazole exposure and other risk factors for SCC

At the univariate level (Table 3), exposure to voriconazole alone was associated with an increased risk for SCC compared with unexposed (hazard ratio [HR] 2.55, 95% confidence interval [CI] 1.42-4.60). An increasing risk of SCC was observed with increasing age. A “dose-response relationship” was observed between exposure to sunlight and SCC. LT recipients with medium sunlight exposure (HR 3.37, 95% CI 1.42-8.0) and high sunlight exposure (HR 4.40, 95% CI 3.50-23.49) were at higher risk for SCC compared with recipients with low sunlight exposure. A history of malignancy before LT was also associated with SCC (HR 22.06, 95% CI 9.97-48.81). With regard to immunosuppressive agents, exposure to alemtuzumab (HR 2.44, 95% CI 1.23-4.80), cyclosporine/azathioprine (HR 7.11, 95% CI 1.56-32.50), and tacrolimus/mycophenolate (HR 4.35, 95% CI 1.00-18.99) was each significantly associated with the risk of SCC at the univariate level. No patients exposed to antithymocyte globulin developed SCC.

In a multivariable model analyzing voriconazole, other azoles, and immunosuppressive agents as time-dependent covariates, exposure to voriconazole alone (adjusted HR 2.39, 95% CI 1.31-4.37) and exposure to voriconazole and other azole(s) (adjusted HR 3.45, 95% CI 1.35-8.0) compared with unexposed were associated with SCC after controlling for confounders (Table 4). Those exposed to other azoles alone did not demonstrate an increased hazard for SCC compared with unexposed individuals alone (adjusted HR 0.80, 95% CI 0.26-2.49).

3.3 Effect of dose, duration, and indication of voriconazole exposure on the risk of SCC

A multivariable model adjusting for potential confounders suggested that an increase in the mean daily exposure to voriconazole equal to 1 defined daily dose (400 mg daily) increased the risk of SCC by 2.70-fold (adjusted HR 2.70, 95% CI 1.53-4.78) in LT recipients. In addition, the cumulative duration of both voriconazole and other azole(s) exposure and the risk of SCC were modeled in a separate multivariable model adjusting for potential confounders. Compared with unexposed to any azole, cumulative voriconazole exposure of >180 days (adjusted HR 3.52, 95% CI 1.59-7.79) was associated with a higher risk of SCC. The model did not suggest an increased risk of SCC with increasing duration of other azoles (Table 4).

4 DISCUSSION

This multicenter, retrospective, cohort study suggests a 2.4-fold increased risk of SCC in LT recipients exposed to voriconazole
TABLE 2 Incidence rate (per 1000 person-years) of squamous cell carcinoma by 4 treatment exposure categories: overall and by time since lung transplantation

| Characteristic | Overall incidence rate | Year 1 post-LT | Year 2 post-LT | Year 3 post-LT | Year 4 post-LT | Year 5 post-LT | Year 6 post-LT | Year 7 post-LT |
|----------------|------------------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|
|                | Unexposed, person-y    | Exposed to voriconazole alone, person-y | Exposed to other azole alone, person-y | Exposed to voriconazole and other azole(s), person-y |
| Overall incidence rate | (No. SCC cases/person-y) | 13.1 (17/1299) | 33.4 (28/837) | 10.4 (5/481) | 21.7 (5/230) |
| All patients   |                        | 2.4 (1/415)   | 4.4 (1/227)   | 0 (0/118)     | 34.2 (1/29)    |
| Year 1 post-LT |                        | 4.3 (3/698)   | 20.3 (9/444)  | 4.2 (1/238)   | 10.4 (1/96)    |
| Year 2 post-LT |                        | 7.5 (7/934)   | 17.8 (11/618) | 8.9 (3/336)   | 12.6 (2/158)   |
| Year 3 post-LT |                        | 8.9 (10/1126) | 28.1 (21/749) | 9.7 (4/413)   | 24.6 (5/203)   |
| Year 4 post-LT |                        | 9.1 (11/1209) | 33.7 (27/802) | 8.9 (4/447)   | 22.9 (5/219)   |
| Year 5 post-LT |                        | 11.1 (14/1266) | 34.0 (28/824) | 10.7 (5/468)  | 22.1 (5/226)   |
| Year 6 post-LT |                        | 13.1 (17/1294) | 33.6 (28/834) | 10.5 (5/478)  | 21.7 (5/230)   |

LT, lung or heart-lung transplantation; SCC, squamous cell carcinoma.

compared with those unexposed, after controlling for important confounding variables. The study findings corroborate previous studies examining the association between voriconazole exposure and SCC or nonmelanoma skin cancer and suggest a dose-response relationship (ie, increasing dose or duration of voriconazole increases the risk of SCC). This risk increased to 3.5-fold when LT recipients were exposed to voriconazole for a cumulative period of >180 days compared with those unexposed and to 2.7-fold for every 400-mg increase in the mean daily dose. LT recipients receiving prophylaxis had a longer duration of exposure compared with those receiving treatment only and were at an increased hazard for SCC.

The impact of voriconazole exposure on the risk of SCC in LT recipients has been suggested in several epidemiologic studies; however, this is the first multicenter study, and largest study overall, that has attempted to control for the potential confounding effect of immunosuppression use and exposure to sunlight. Incidence of SCC varies across studies depending on the study methodology used, including follow-up time, but also likely as a result of varying patient demographic and clinical characteristics, including the use of different immunosuppression protocols during distinct transplantation eras. A retrospective cohort study by Singer and coworkers evaluated 327 LT recipients during 20 years and reported a crude incidence of 16.5% in patients exposed to voriconazole compared with 11.8% among those unexposed, with an overall median time from LT to SCC diagnosis of 3.6 years. 

This study also suggested that any exposure to voriconazole was associated with a 2.6-fold increase in the risk of cutaneous SCC adjusted for age, sex, and race (HR 2.62, 95% CI 1.21-5.65), consistent with our finding of increased risk for SCC; however, importantly, this did not account for the type or the duration or intensity of immunosuppression.

A single-center retrospective cohort study of 455 LT recipients showed that voriconazole exposure was associated with risk of SCC, adjusted for age, sex, and race (adjusted HR 1.73, 95% CI 1.04-2.88). In contrast to our study, they were unable to account for voriconazole exposure during hospitalization, nor did they control for the type and intensity of immunosuppression, all of which may have biased their estimate.

Although exposure to voriconazole was associated with an increased risk of SCC, our study also suggests a potential dose-response relationship. Evidence from a retrospective cohort study suggests that longer duration of voriconazole therapy, but not cumulative dose, is an independent risk factor for SCC (odds ratio 1.8, 95% CI 1.3-2.6). Rather than cumulative dose, the present study modeled the mean cumulative dose as the summary exposure measure in an effort to better specify the intensity of voriconazole therapy. Two other studies provide opposing evidence, with both reporting that neither increasing voriconazole duration nor increasing mean cumulative dose was associated with increased risk of skin cancer. 

Although both included measures of immunosuppression use, one of the studies failed to account for duration of use and the other used a large prescription claims database, which did not contain data on voriconazole use during hospitalization, to inform both voriconazole exposure and the outcome of nonmelanoma skin cancer. The final model in the present study not only accounted for both inpatient/outpatient exposure to voriconazole and individual immunosuppressive agents, including dose and duration, but also controlled for other patient-specific indicators of immunosuppression, including episodes of rejection and neutropenia and calcineurin inhibitor whole blood concentrations, which tend to demonstrate a high degree of both interpatient and intrapatient variability that may not correlate with dose administered.

Although the means by which voriconazole may lead to the development of SCC has not been fully elucidated, it has been proposed that voriconazole itself, or one of its metabolites, may cause ultraviolet-induced DNA damage or disrupt mechanisms used to repair damaged DNA. This process may initially present clinically as photosensitivity or phototoxicity, followed by the development of a cutaneous malignancy in some patients, perhaps accelerated by intense immunosuppression or other immune impairment. Thus far, the association...
### TABLE 3

Univariate analyses evaluating the association between 4 treatment exposure categories and the risk of squamous cell carcinoma in patients receiving a lung or heart-lung transplant (N = 900)

| Characteristics | HR | 95% CI | P-value |
|-----------------|----|--------|---------|
| **Treatment exposure categories** |    |        |         |
| Unexposed | Ref |        |         |
| Exposure to voriconazole alone | 2.55 | 1.42, 4.60 | .002 |
| Exposure to otherazole alone | 0.73 | 0.27, 1.98 | .541 |
| Exposure to voriconazole and other azole(s) | 1.47 | 0.53, 4.05 | .455 |
| **Age, y** |    |        |         |
| 18-29 | Ref |        |         |
| 30-49 | 6.66 | 0.88, 50.70 | .067 |
| 50-59 | 9.22 | 1.25, 68.20 | .030 |
| ≥60 | 15.04 | 2.05, 110.08 | .008 |
| **Sex** |    |        |         |
| Female | Ref |        |         |
| Male | 1.49 | 0.86, 2.56 | .153 |
| **Race/ethnicity** |    |        |         |
| Other | Ref |        |         |
| White | 2.08 | 0.30, 14.52 | .459 |
| Missing | 1.51 | 0.22, 10.50 | .674 |
| **Occupation** |    |        |         |
| Indoor | Ref |        |         |
| Outdoor | 1.57 | 0.69, 3.56 | .281 |
| Mixed | 0.46 | 0.26, 0.83 | .009 |
| **Chemical exposure** |    |        |         |
| No | Ref |        |         |
| Yes | 0.69 | 0.21, 2.25 | .537 |
| **Geographical location** |    |        |         |
| Spain | Ref |        |         |
| Australia | 24.8 | 3.17, 193.21 | .002 |
| Canada | 5.73 | 0.75, 43.65 | .092 |
| France | - | - | - |
| Germany | 1.68 | 0.15, 18.41 | .673 |
| Italy | - | - | - |
| Netherlands | 4.56 | 0.51, 40.6 | .174 |
| Switzerland | - | - | - |
| United States | 19.5 | 2.63, 144.84 | .004 |
| **Sun exposure** |    |        |         |
| Low | Ref |        |         |
| Medium | 3.37 | 1.42, 8.0 | .006 |
| High | 4.40 | 3.50, 23.49 | <.001 |

(Continues)
between voriconazole plasma concentrations and phototoxicity has been poorly studied, with limited reports of phototoxic skin reactions due to voriconazole being described as idiosyncratic.\textsuperscript{15–17} Optimizing voriconazole dosing for an individual can be challenging as a result of considerable interpatient and intrapatient variability in plasma concentrations.\textsuperscript{31} Nonetheless, there have been recommendations published with respect to a possible upper limit for therapeutic drug levels in an

### TABLE 3 (Continued)

| Characteristics                  | HR   | Lower | Upper | P-value |
|----------------------------------|------|-------|-------|---------|
| Days in hospital at the time of LT |      |       |       |         |
| 1-14                             | Ref  |       |       |         |
| 15-30                            | 0.48 | 0.24  | 0.94  | .033    |
| >30                              | 0.42 | 0.20  | 0.87  | .020    |
| Days in ICU at the time of LT    |      |       |       |         |
| 1-14                             | Ref  |       |       |         |
| 15-30                            | 0.56 | 0.21  | 1.51  | .252    |
| >30                              | 0.40 | 0.17  | 0.98  | .045    |
| IL-2 antagonist                   |      |       |       |         |
| No                               | Ref  |       |       |         |
| Yes                              | 0.67 | 0.38  | 1.20  | .176    |
| Alemtuzumab                      |      |       |       |         |
| No                               | Ref  |       |       |         |
| Yes                              | 2.44 | 1.23  | 4.80  | .010    |
| Antithymocyte globulin use       |      |       |       |         |
| No                               | Ref  |       |       |         |
| Yes                              | -    | -     | -     | -       |
| Supratherapeutic CNI episodes\textsuperscript{a} |      |       |       |         |
| 0                                | Ref  |       |       |         |
| 1-2                              | 0.69 | 0.37  | 1.30  | .253    |
| 3-4                              | 1.30 | 0.64  | 2.66  | .463    |
| >4                               | 1.18 | 0.42  | 3.32  | .752    |
| Steroid mean daily dose (mg per day) |      |       |       |         |
| <10                              | Ref  |       |       |         |
| 10-20                            | 1.17 | 0.66  | 2.08  | .587    |
| >20                              | 1.34 | 0.54  | 3.31  | .524    |
| Cyclosporine use                 |      |       |       |         |
| No                               | Ref  |       |       |         |
| Yes                              | 0.64 | 0.38  | 1.08  | .094    |
| Tacrolimus                       |      |       |       |         |
| No                               | Ref  |       |       |         |
| Yes                              | 1.04 | 0.58  | 1.86  | .898    |
| Steroid use                      |      |       |       |         |
| No                               | Ref  |       |       |         |
| Yes                              | -    | -     | -     | -       |
| Mycophenolate                    |      |       |       |         |
| No                               | Ref  |       |       |         |
| Yes                              | 0.60 | 0.35  | 1.04  | .067    |
| Azathioprine                     |      |       |       |         |
| No                               | Ref  |       |       |         |
| Yes                              | 1.21 | 0.71  | 2.07  | .49     |
| Sirolimus                        |      |       |       |         |
| No                               | Ref  |       |       |         |
| Yes                              | 1.37 | 0.53  | 3.57  | .518    |

\textsuperscript{a}Subjectively classified according to whether subject would spend majority of time indoors/outdoors/mixed.

\textsuperscript{b}Includes insecticides/herbicides/fungicides, petroleum/diesel/tar products, dry cleaning agents, asbestos, and fiberglass.

\textsuperscript{c}According to respective study center's geographical location by latitude: low (>45° latitude), medium (35-45° latitude), and high (<35° latitude).

\textsuperscript{d}Includes rheumatoid arthritis, systemic lupus erythematosus, Henoch-Schönlein purpura, and psoriasis.

\textsuperscript{e}Not including squamous cell carcinoma, basal cell carcinoma, and melanoma.

\textsuperscript{f}Absolute neutrophil counts <500 cells/mm\textsuperscript{3}.

\textsuperscript{g}Elevated CNI levels were defined as cyclosporine trough >350 μg/L or tacrolimus trough >20 μg/L.

\textsuperscript{h}Combined immunosuppressive agents are usually prescribed. CNIs, including cyclosporine and tacrolimus, have been the cornerstones of an immunosuppressive regimen, which usually includes ≥2 additional agents, almost always glucocorticoids, and a purine antagonist (mycophenolic acid or azathioprine). Sirolimus (rapamycin) has been used as a substitute for CNIs. The choice of agents is often immunosuppressive protocol driven but is usually adapted to each recipient's risk profile or intolerance to 1 of these agents.

\textsuperscript{i}Includes doxycycline, hydroxychloroquine, nifedipine, diltiazem, glyburide, naproxen, piroxicam, and isotretinoin.
Carcinoma of the skin between voriconazole exposure and the risk of squamous cell carcinoma of the skin

TABLE 4 Cox proportional hazards models for the relation between voriconazole exposure and the risk of squamous cell carcinoma of the skin

| Model                                      | HR   | 95% CI   | P-value |
|--------------------------------------------|------|----------|---------|
| Full cohort, un-adjusted, time-dependent covariates |      |          |         |
| Unexposed                                  | Ref  |          |         |
| Exposure to voriconazole alone             | 2.55 | 1.42-4.60| .002    |
| Exposure to other azole alone              | 0.73 | 0.27-1.98| .541    |
| Exposure to voriconazole and otherazole(s)| 1.47 | 0.53-4.05| .455    |
| Full cohort, adjusted, time-dependent covariates⁴ |      |          |         |
| Unexposed                                  | Ref  |          |         |
| Exposure to voriconazole alone             | 2.39 | 1.31-4.37| .005    |
| Exposure to other azole alone              | 0.80 | 0.26-2.49| .698    |
| Exposure to voriconazole and otherazole(s)| 3.45 | 1.07-11.06| .038   |
| Full cohort, adjusted, time-dependent covariate⁴ |      |          |         |
| Mean voriconazole daily dose (per 1 DDD increment)⁵ | 2.70 | 1.53-4.78| .001    |
| Full cohort, adjusted, time-dependent covariates, by duration⁴ |      |          |         |
| No exposure to anyazole                    |      |          |         |
| Exposure to voriconazole 1-90 days         | 0.45 | 0.10-2.10| .311    |
| Exposure to voriconazole 91-180 days       | 2.23 | 0.94-5.30| .070    |
| Exposure to voriconazole >180 days         | 3.52 | 1.59-7.79| .002    |
| Exposure to other azole 1-90 days ⁶        |      |          |         |
| Exposure to other azole 91-180 days        | 1.59 | 0.35-7.34| .551    |
| Exposure to other azole >180 days          | 1.12 | 0.24-5.30| .887    |
| Full cohort, adjusted, time-dependent covariates, by indication⁴ |      |          |         |
| Unexposed                                  | Ref  |          |         |
| Prophylaxis alone                          | 2.77 | 1.53-5.00| .001    |
| Treatment alone                            | 1.16 | 0.50-2.67| .727    |
| Prophylaxis and treatment                  | 2.37 | 0.55-10.11| .244   |

CI, confidence interval; DDD, defined daily dose; HR, hazard ratio; Ref, reference category.

⁴Adjusted for age, sex, immunosuppression regimen, mean cyclosporine level, mean tacrolimus level, sun exposure, history of malignancy pretransplantation, transplant rejection episodes, and underlying disease.

⁵DDD (voriconazole, 1 DDD = 0.4 g).

⁶No events occurred for this group.

Despite the strengths of this study, including a large and generalizable cohort of LT recipients and accounting for important confounding factors, limitations did still exist, including the retrospective observational nature of the dataset and the potential for inaccuracies in medical records. Given that proxy variables were used to control for confounding (ie, immunosuppressive agents in the absence of a comprehensive measure of immune status; geographical location/latitude of LT center in the absence of individual-level data on exposure to sunlight in medical charts), residual confounding due to these factors cannot be completely ruled out. Further, because immunosuppression and sun exposure are center and region-specific, it is difficult to separate the effect of center practices versus geographic location. Caution should be exercised when generalizing the findings to more-diverse populations (ie, all voriconazole-treated patient populations) given that patients with LT are a special patient population with unique factors that make them more susceptible to SCC of the skin.

In summary, this study using real-world data from across Europe, North America, and Australia suggests that voriconazole is associated with an increased risk of SCC in LT recipients and that this risk increases with increasing dose or duration of voriconazole. There is currently no universally accepted recommendation for an optimal antifungal prophylactic strategy in LT recipients. Voriconazole has been shown to decrease morbidity and mortality in a variety of clinical circumstances, including primary treatment of IA in LT recipients; however, voriconazole’s association with an increased risk in SCC in susceptible LT recipients should be weighed carefully with its benefits in preventing or treating invasive fungal infections. Further, LT recipients who require prolonged voriconazole prophylaxis or treatment should be counselled regarding sun avoidance and sunscreen and have close dermatologic follow-up.

ACKNOWLEDGMENTS

We thank Dr John Orazem for advice on data analysis, Dr Quazi Ataher for help in data interpretation and critical review of the draft manuscript, and Dr Marcia Ruiz, Ken Schanbacher, Yinka Akinlolu, and Rhea Pavan for research coordination and support. Medical writing support was provided by Martin Bell at Complete Medical Communications and was funded by Pfizer. Sources of support: This study was sponsored by Pfizer.

DISCLOSURE

The authors of the manuscript have conflicts of interest to disclose as described by the American Journal of Transplantation. Drs Shahid Husain, Lianne G. Singer, and Bassem Hamandi are employees of University Health Network, University of Toronto, Ontario, Canada, which received financial support from Pfizer in connection with the study and development of the manuscript. Dr Fernanda P. Silveira is an employee of the University of Pittsburgh, Pittsburgh, PA, USA, which received financial support for the conduct of this study from the University Health Network/University of Toronto. University Health Network received financial support from Pfizer.
in connection with the study and development of the manuscript. Dr Amaro Solé is an employee of the University Hospital La Fe, University of Valencia, Valencia, Spain, which received financial support for the conduct of this study from the University Health Network/University of Toronto. University Health Network received financial support from Pfizer in connection with the study and development of the manuscript. Dr Denis Hadjiliadis is an employee of the University of Pennsylvania, Philadelphia, PA, USA, which received financial support for the conduct of this study from the University Health Network/University of Toronto. University Health Network received financial support from Pfizer in connection with the study and development of the manuscript. Dr Piedad M. Ussetti is an employee of the Hospital Puerta de Hierro, Madrid, Spain, which received financial support for the conduct of this study from the University Health Network/University of Toronto. University Health Network received financial support from Pfizer in connection with the study and development of the manuscript. Dr Christine Fegbeutel is an employee of the Hanover Medical School, Hanover, Germany, which received financial support for the conduct of this study from the University Health Network/University of Toronto. University Health Network received financial support from Pfizer in connection with the study and development of the manuscript. Dr Erik A. Verschuuren is an employee of the University Medical Centre Groningen, University of Groningen, Groningen, Netherlands, which received financial support for the conduct of this study from the University Health Network/University of Toronto. University Health Network received financial support from Pfizer in connection with the study and development of the manuscript. Dr Peter V. Chin-Hong is an employee of the University of California San Francisco, San Francisco, CA, USA, which received financial support for the conduct of this study from the University Health Network/University of Toronto. University Health Network received financial support from Pfizer in connection with the study and development of the manuscript. Dr Chien-Li Holmes-Liew is an employee of the Royal Adelaide Hospital, Adelaide, Australia, which received financial support for the conduct of this study from the University Health Network/University of Toronto. University Health Network received financial support from Pfizer in connection with the study and development of the manuscript. Dr Paolo A. Grossi is an employee of the University of Insubria, Varese, Italy, which received financial support for the conduct of this study from the University Health Network/University of Toronto. University Health Network received financial support from Pfizer in connection with the study and development of the manuscript. Dr Oriol Manuel is an employee of the University Hospital of Lausanne, Lausanne, Switzerland, which received financial support for the conduct of this study from the University Health Network/University of Toronto. University Health Network received financial support from Pfizer in connection with the study and development of the manuscript. Dr Deborah J. Levine is an employee of the University of Texas Health Science Center San Antonio, San Antonio, TX, USA, which received financial support for the conduct of this study from the University Health Network/University of Toronto. University Health Network received financial support from Pfizer in connection with the study and development of the manuscript. Dr Richard G. Barbers is an employee of the KECK Medical Center of the University of Southern California, Los Angeles, CA, USA, which received financial support for the conduct of this study from the University Health Network/University of Toronto. University Health Network received financial support from Pfizer in connection with the study and development of the manuscript. Drs Jalal Aram, Jean Yan, Jingping Mo, and Muhammad Younus are employees of Pfizer and own stock in Pfizer.

ORCID

L. G. Singer http://orcid.org/0000-0002-2693-8676

REFERENCES

1. Euvrard S, Kanitakis J, Claude A. Skin cancers after organ transplantation. N Engl J Med. 2003;348(17):1681-1691.
2. Rashtak S, Dierkhising RA, Kremers WK, Peters SG, Cassivi SD, Otley CC. Incidence and risk factors for skin cancer following lung transplantation. J Am Acad Dermatol. 2015;72(1):92-98.
3. Zwald FO, Brown M. Skin cancer in solid organ transplant recipients: advances in therapy and management: part I. Epidemiology of skin cancer in solid organ transplant recipients. J Am Acad Dermatol. 2011;65(2):253-261; quiz 62.
4. Berg D, Otley CC. Skin cancer in organ transplant recipients: epidemiology, pathogenesis, and management. J Am Acad Dermatol. 2002;47(1):1-17; quiz 8-20.
5. Lindelof B, Jarnvik J, Ternesten-Bratel A, Granath F, Hedblad MA. Mortality and clinicopathological features of cutaneous squamous cell carcinoma in organ transplant recipients: a study of the Swedish cohort. Acta Derm Venereol. 2006;86(3):219-222.
6. Wu J, Oreno IF. Squamous cell carcinoma in solid-organ transplantation. Dermatol Online J. 2002;8(2):4.
7. Yusen RD, Edwards LB, Kucheryavya AY, et al. The Registry of the International Society for Heart and Lung Transplantation: Thirty-second Official Adult Lung and Heart-Lung Transplantation Report–2015; Focus Theme: early Graft Failure. J Heart Lung Transplant. 2015;34(10):1264-1277.
8. Sale A, Salvetti M. Fungal infections after lung transplantation. Curr Opin Pulm Med. 2009;15(3):243-253.
9. Walsh TJ, Anaisiie EJ, Denning DW, et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis. 2008;46(3):327-360.
10. Cadena J, Levine DJ, Angel LF, et al. Antifungal prophylaxis with voriconazole or itraconazole in lung transplant recipients: hepatotoxicity and effectiveness. Am J Transplant. 2009;9(9):2085-2091.
11. Husain S, Chan KM, Palmer SM, et al. Bacteremia in lung transplant recipients in the current era. Am J Transplant. 2006;6(12):3000-3007.
12. Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med. 2002;347(6):408-415.
13. Neoh CF, Snell GI, Kotsimbos T, et al. Antifungal prophylaxis in lung transplantation—a world-wide survey. Am J Transplant. 2011;11(2):361-366.
14. Brunel AS, Fraisse T, Lechiche C, Pinzani V, Mauboussin JM, Sotto A. Multifocal squamous cell carcinomas in an HIV-infected patient with a long-term voriconazole therapy. AIDS. 2008;22(7):905-906.
15. McCarthy KL, Playford EG, Looke DF, Whitby M. Severe photosensitivity causing multifocal squamous cell carcinomas secondary to prolonged voriconazole therapy. Clin Infect Dis. 2007;44(5):e55-e56.
16. Vanacker A, Fabre G, Van DJ, Peetermans WE, Maes B. Aggressive cutaneous squamous cell carcinoma associated with prolonged voriconazole therapy in a renal transplant patient. Am J Transplant. 2008;8(4):877-880.
17. Cowen EW, Nguyen JC, Miller DD, et al. Chronic phototoxicity and aggressive squamous cell carcinoma of the skin in children and adults during treatment with voriconazole. J Am Acad Dermatol. 2010;62(1):31-37.
18. Epaulard O, Saint-Raymond C, Villier C, et al. Multiple aggressive squamous cell carcinomas associated with prolonged voriconazole therapy in four immunocompromised patients. Clin Microbiol Infect. 2010;16(9):1362-1364.
19. Feist A, Lee R, Osborne S, Lane J, Yung G. Increased incidence of cutaneous squamous cell carcinoma in lung transplant recipients taking long-term voriconazole. J Heart Lung Transplant. 2012;31(11):1177-1181.
20. Williams K, Marsh M, Chin-Hong P, Singer J, Arron ST. Voriconazole-associated cutaneous malignancy: a literature review on photocarcinogenesis in organ transplant recipients. Clin Infect Dis. 2014;58(7):997-1002.
21. McLaughlin JM, Equils O, Somerville KT, et al. Risk-adjusted relationship between voriconazole utilization and non-melanoma skin cancer among lung and heart/lung transplant patients. Transpl Infect Dis. 2013;15(4):329-343.
22. Singer JP, Boker A, Metchnikoff C, et al. High cumulative dose exposure to voriconazole is associated with cutaneous squamous cell carcinoma in lung transplant recipients. J Heart Lung Transplant. 2012;31(7):694-699.
23. Vadrnerkar A, Nguyen MH, Mitsani D, et al. Voriconazole exposure and geographic location are independent risk factors for squamous cell carcinoma of the skin among lung transplant recipients. J Heart Lung Transplant. 2010;29(11):1240-1244.
24. Zwald FO, Spratt M, Lemos BD, et al. Duration of voriconazole exposure: an independent risk factor for skin cancer after lung transplantation. Dermato Surg. 2012;38(8):1369-1374.
25. Wojenski DJ, Bartoo GT, Merten JA, et al. Voriconazole exposure and the risk of cutaneous squamous cell carcinoma in allogeneic hematopoietic stem cell transplant patients. Transpl Infect Dis. 2015;17(2):250-258.
26. WHO Collaborating Centre For Drug Statistics [updated 2016-12-192017-03-29]. https://www.whocc.no/atic_ddi_index/. Accessed September 18, 2015.
27. de Vocht F, Burstyn I, Sanguanchaiyakrit N. Rethinking cumulative exposure in epidemiology, again. J Exposure Sci Environ Epidemiol. 2015;25(5):467-473.
28. Schiff J, Cole E, Cantarovich M. Therapeutic monitoring of calcineurin inhibitors for the nephrologist. Clin J Am Soc Nephrol. 2007;2(2):374-384.
29. Epaulard O, Leccia MT, Blanche S, et al. Phototoxicity and photocarcinogenesis associated with voriconazole. Medecine et maladies infectieuses. 2011;41(12):639-645.
30. Epaulard O, Villier C, Ravaud P, et al. A multistep voriconazole-related phototoxic pathway may lead to skin carcinoma: results from a French nationwide study. Clin Infect Dis. 2013;57(12):182-e188.
31. Trifillo S, Pennick G, Pi J, et al. Monitoring plasma voriconazole levels may be necessary to avoid subtherapeutic levels in hematopoietic stem cell transplant recipients. Cancer. 2007;109(8):1532-1535.
32. Ashbee HR, Barnes RA, Johnson EM, Richardson MD, Gorton R, Hope WW. Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology. J Antimicrob Chemother. 2014;69(5):1162-1176.
33. Hamada Y, Tokimatsu I, Mikamo H, et al. Practice guidelines for therapeutic drug monitoring of voriconazole: a consensus review of the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring. J Infect Chemother. 2013;19(3):381-392.
34. Lavenderie M, Bow EJ, Rotstein C, et al. Therapeutic drug monitoring for triazoles: a needs assessment review and recommendations from a Canadian perspective. Can J Infect Dis Med Microbiol. 2014;25(6):327-343.

SUPPORTING INFORMATION

Additional Supporting Information may be found online in the supporting information tab for this article.